SHANGHAI, China, April 10, 2026
Oricell Therapeutics Holdings Limited has successfully closed a $110 million pre-IPO financing round, marking a major milestone in its mission to accelerate the global development of next-generation CAR-T therapies for solid tumors. The funding round, co-led by prominent healthcare investors including Vivo Capital and Qiming Venture Partners, underscores strong investor confidence in Oricell’s innovative immunotherapy platforms and clinical-stage pipeline. The proceeds will be strategically deployed to advance clinical trials, expand global operations, and strengthen manufacturing and technology capabilities, positioning the company for upcoming capital market milestones and IPO readiness.
Strategic Funding to Accelerate Global CAR-T Development
The newly secured capital will play a critical role in driving Oricell’s international expansion strategy and clinical pipeline advancement, particularly in the rapidly evolving field of cell and gene therapy for oncology. With increasing demand for effective treatments targeting solid tumors, Oricell is focusing on bridging one of the most challenging gaps in cancer therapy. The company has already demonstrated proof-of-concept (POC) success across multiple programs, reinforcing its position as a frontrunner in CAR-T innovation.
Oricell’s proprietary technology ecosystem, comprising the Ori®Ab antibody discovery platform, Ori®Armoring T-cell enhancement system, and OnGo rapid CMC manufacturing capabilities, provides a competitive advantage in developing scalable and high-performance CAR-T therapies. This integrated “platform plus pipeline” model enables the company to accelerate drug development timelines while maintaining high-quality clinical outcomes, a critical factor in the competitive immunotherapy landscape.
Lead CAR-T Candidate Targets Liver Cancer Breakthrough
Advertisement
At the forefront of Oricell’s pipeline is Ori-C101, a GPC3-targeted autologous CAR-T therapy designed for the treatment of advanced hepatocellular carcinoma (HCC), one of the most prevalent and deadly forms of liver cancer globally. The therapy has already progressed through investigator-initiated trials and a registrational Phase 1 study, demonstrating a best-in-class safety and efficacy profile. These promising clinical results have been showcased at major scientific forums such as the ASCO Annual Meeting, highlighting Oricell’s growing influence in the global oncology community.
With plans to initiate pivotal clinical trials, Ori-C101 is positioned as a potential first-in-class CAR-T therapy for solid tumors, a breakthrough that could significantly transform treatment paradigms in liver cancer. In addition to its lead asset, Oricell is advancing a diversified pipeline of next-generation CAR-T modalities, including in vivo CAR-T therapies, rapid-manufacturing approaches, and secreted CAR-T technologies, further expanding its therapeutic reach across multiple oncology indications.
Positioning as a Global Leader in Cell Therapy Innovation
Oricell’s latest financing reflects a broader industry trend toward increased investment in advanced immunotherapies and precision oncology solutions. The company’s ability to secure backing from global healthcare funds, sovereign wealth investors, and leading venture capital firms highlights its strong scientific foundation, clinical execution capabilities, and global commercialization strategy.
Beyond its pipeline, Oricell has demonstrated excellence in regulatory strategy and international clinical development, with key programs receiving approvals from major regulatory bodies, including the U.S. Food and Drug Administration and China’s NMPA. Its candidate OriCAR-017 has also earned Orphan Drug Designation and Fast Track status, further validating its potential to address critical unmet medical needs in oncology.
As the company approaches pivotal inflection points, including late-stage clinical trials and potential IPO activities, Oricell is well-positioned to become a dominant force in the global CAR-T therapy market. By combining cutting-edge science, scalable manufacturing, and a robust clinical pipeline, the company aims to deliver transformative cancer treatments that improve survival outcomes and quality of life for patients worldwide.
With solid tumors representing one of the most challenging frontiers in oncology, Oricell’s continued progress signals a new era of innovation in cell therapy, offering renewed hope for patients and redefining the future of precision cancer immunotherapy.
Source: Oricell Therapeutics press release
